Laboratorios Farmaceuticos ROVI (ROVI.MC) Stock Price

Laboratorios Farmaceuticos ROVI Price

🇪🇸BME·CLOSED
58.35EUR
Market closed
Today +/-
Today %

Laboratorios Farmaceuticos ROVI (ROVI.MC) Stock | ISIN ES0157261019 | WKN A0M0GQ. The current Laboratorios Farmaceuticos ROVI stock price is 58.35 EUR (2026). Revenue is 833.6 M EUR. Net income is 157.52 M EUR. The P/E ratio is 18.97. Market capitalization is 2.99 B EUR. Laboratorios Farmaceuticos ROVI operates in the Health sector.

Laboratorios Farmaceuticos ROVI stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Laboratorios Farmaceuticos ROVI over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Laboratorios Farmaceuticos ROVI stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Laboratorios Farmaceuticos ROVI's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Laboratorios Farmaceuticos ROVI Stock Price History
DateLaboratorios Farmaceuticos ROVI Price
Access this data via the Eulerpool API
Get Free API Key

Laboratorios Farmaceuticos ROVI Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2005
82.6 M EUR
3.3 M EUR
4.1 M EUR
Jan 1, 2006
105 M EUR
13.4 M EUR
10.9 M EUR
Jan 1, 2007
100.7 M EUR
18.4 M EUR
15 M EUR
Jan 1, 2008
127.5 M EUR
28.3 M EUR
23.5 M EUR
Jan 1, 2009
141.8 M EUR
25.5 M EUR
20.1 M EUR
Jan 1, 2010
158.6 M EUR
26 M EUR
24.6 M EUR
Jan 1, 2011
184.7 M EUR
19 M EUR
18.1 M EUR
Jan 1, 2012
201.9 M EUR
21.7 M EUR
19.5 M EUR
Jan 1, 2013
217.6 M EUR
25.4 M EUR
23 M EUR
Jan 1, 2014
238.05 M EUR
27.43 M EUR
24.12 M EUR
Jan 1, 2015
246.01 M EUR
21.84 M EUR
19.81 M EUR
Jan 1, 2016
265.17 M EUR
28.3 M EUR
26.09 M EUR
Jan 1, 2017
275.65 M EUR
19.01 M EUR
17.24 M EUR
Jan 1, 2018
303.2 M EUR
17.46 M EUR
17.9 M EUR
Jan 1, 2019
381.31 M EUR
43.18 M EUR
39.27 M EUR

Laboratorios Farmaceuticos ROVI Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 12, 2026, 6:34 AM
 
REVENUE (B EUR)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M EUR)
NET INCOME (M EUR)
NET INCOME GROWTH (%)
DIV. (EUR)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
2022202320242025e2026e2027e2028e2029e
0.820.830.760.750.830.991.081.11
26.081.47-7.96-2.111.5118.499.222.97
63.5359.3562.6563.9957.3848.4344.3443.06
519492478478478478478478
199170136126157214277257
30.07-14.57-20-7.3524.636.3129.44-7.22
0.961.291.10.940.60.84--
152.6334.38-14.73-14.55-36.1740––
53.4753.1951.2151.2151.2151.2151.2151.21
––––––––
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Laboratorios Farmaceuticos ROVI generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Laboratorios Farmaceuticos ROVI retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Laboratorios Farmaceuticos ROVI's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Laboratorios Farmaceuticos ROVI has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Laboratorios Farmaceuticos ROVI's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Laboratorios Farmaceuticos ROVI stock margins

The Laboratorios Farmaceuticos ROVI margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Laboratorios Farmaceuticos ROVI. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Laboratorios Farmaceuticos ROVI.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2005
71.91 %
4 %
4.96 %
Jan 1, 2006
71.81 %
12.76 %
10.38 %
Jan 1, 2007
68.22 %
18.27 %
14.9 %
Jan 1, 2008
72.31 %
22.2 %
18.43 %
Jan 1, 2009
67.28 %
17.98 %
14.17 %
Jan 1, 2010
60.4 %
16.39 %
15.51 %
Jan 1, 2011
62.43 %
10.29 %
9.8 %
Jan 1, 2012
62.61 %
10.75 %
9.66 %
Jan 1, 2013
60.98 %
11.67 %
10.57 %
Jan 1, 2014
60.27 %
11.52 %
10.13 %
Jan 1, 2015
60.54 %
8.88 %
8.05 %
Jan 1, 2016
57.75 %
10.67 %
9.84 %
Jan 1, 2017
60.77 %
6.9 %
6.25 %
Jan 1, 2018
57.58 %
5.76 %
5.9 %
Jan 1, 2019
56.31 %
11.33 %
10.3 %

Laboratorios Farmaceuticos ROVI Stock Revenue, EBIT, Earnings per Share

The Laboratorios Farmaceuticos ROVI earnings per share therefore indicates how much revenue Laboratorios Farmaceuticos ROVI has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2005
1.65 EUR
0.07 EUR
0.08 EUR
Jan 1, 2006
2.1 EUR
0.27 EUR
0.22 EUR
Jan 1, 2007
2.01 EUR
0.37 EUR
0.3 EUR
Jan 1, 2008
2.56 EUR
0.57 EUR
0.47 EUR
Jan 1, 2009
2.86 EUR
0.51 EUR
0.41 EUR
Jan 1, 2010
3.19 EUR
0.52 EUR
0.49 EUR
Jan 1, 2011
3.72 EUR
0.38 EUR
0.36 EUR
Jan 1, 2012
4.06 EUR
0.44 EUR
0.39 EUR
Jan 1, 2013
4.37 EUR
0.51 EUR
0.46 EUR
Jan 1, 2014
4.77 EUR
0.55 EUR
0.48 EUR
Jan 1, 2015
4.97 EUR
0.44 EUR
0.4 EUR
Jan 1, 2016
5.41 EUR
0.58 EUR
0.53 EUR
Jan 1, 2017
5.6 EUR
0.39 EUR
0.35 EUR
Jan 1, 2018
5.92 EUR
0.34 EUR
0.35 EUR
Jan 1, 2019
6.91 EUR
0.78 EUR
0.71 EUR

Laboratorios Farmaceuticos ROVI business model & stock analysis

Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products.

Laboratorios Farmaceuticos ROVI SWOT Analysis

Strengths

Laboratorios Farmaceuticos ROVI SA has several strengths that contribute to its success:

  • Strong market presence and brand reputation.
  • Diverse product portfolio offering a wide range of pharmaceuticals.
  • Advanced research and development capabilities for innovative drugs.
  • Effective distribution network ensuring wide product availability.
  • Robust financial performance and solid profitability.

Weaknesses

Despite its strengths, Laboratorios Farmaceuticos ROVI SA also has some weaknesses:

  • Dependency on a few key products for a significant portion of revenues.
  • Limited geographical presence, concentrated mainly in certain regions.
  • Relatively low market share compared to larger pharmaceutical companies.
  • High research and development costs impacting profitability.

Opportunities

There are several opportunities available for Laboratorios Farmaceuticos ROVI SA:

  • Expanding into new international markets to diversify revenue streams.
  • Leveraging technological advancements to develop innovative products.
  • Collaborating with other pharmaceutical companies for joint research and development.
  • Focusing on emerging markets with growing healthcare needs.

Threats

Laboratorios Farmaceuticos ROVI SA faces certain threats that may impact its business:

  • Intense competition from other pharmaceutical companies.
  • Changes in regulations and government policies affecting the industry.
  • Economic downturns leading to decreased consumer spending on healthcare.
  • Potential patent expirations and generic drug competition.

Laboratorios Farmaceuticos ROVI Eulerpool Fair Value

Laboratorios Farmaceuticos ROVI historical P/E ratio, EBIT multiple, and P/S ratio

Laboratorios Farmaceuticos ROVI annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Laboratorios Farmaceuticos ROVI shares outstanding

The number of shares was Laboratorios Farmaceuticos ROVI in 2025 — This indicates how many shares 51.21 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2005
50 M base_Shares
Jan 1, 2006
50 M base_Shares
Jan 1, 2007
50 M base_Shares
Jan 1, 2008
49.9 M base_Shares
Jan 1, 2009
49.6 M base_Shares
Jan 1, 2010
49.7 M base_Shares
Jan 1, 2011
49.7 M base_Shares
Jan 1, 2012
49.7 M base_Shares
Jan 1, 2013
49.8 M base_Shares
Jan 1, 2014
49.89 M base_Shares
Jan 1, 2015
49.54 M base_Shares
Jan 1, 2016
49.03 M base_Shares
Jan 1, 2017
49.26 M base_Shares
Jan 1, 2018
51.22 M base_Shares
Jan 1, 2019
55.18 M base_Shares

Laboratorios Farmaceuticos ROVI Dividend History

18 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.94EUR↓ 15.3%1×
Jul 14, 20250.94EUR↓ 15.3%1/1
20241.1EUR↓ 14.7%1×
20231.29EUR↑ 35.4%1×
20220.96EUR↑ 150.7%1×
20210.38EUR↑ 117.7%1×
20200.18EUR↑ 119.4%1×
20190.08EUR↓ 33.9%1×
20180.12EUR↓ 34.0%1×
20170.18EUR↑ 31.7%1×
20160.14EUR↓ 17.8%1×

Laboratorios Farmaceuticos ROVI dividend history and estimates

In 2025, Laboratorios Farmaceuticos ROVI paid a dividend amounting to 0.94 EUR. Dividend means that Laboratorios Farmaceuticos ROVI distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Invalid Date
0.08 EUR
0.08 EUR
Invalid Date
0.09 EUR
0.09 EUR
Jan 1, 2010
0.14 EUR
0 EUR
Jan 1, 2011
0.17 EUR
0 EUR
Jan 1, 2012
0.13 EUR
0 EUR
Jan 1, 2013
0.14 EUR
0 EUR
Jan 1, 2014
0.16 EUR
0 EUR
Jan 1, 2015
0.17 EUR
0 EUR
Jan 1, 2016
0.14 EUR
0 EUR
Jan 1, 2017
0.18 EUR
0 EUR
Jan 1, 2018
0.12 EUR
0 EUR
Jan 1, 2019
0.08 EUR
0 EUR
Jan 1, 2020
0.18 EUR
0 EUR
Jan 1, 2021
0.38 EUR
0 EUR
Jan 1, 2022
0.96 EUR
0 EUR

Laboratorios Farmaceuticos ROVI dividend payout ratio

In 2025, Laboratorios Farmaceuticos ROVI had a payout ratio of 21.09%. The payout ratio indicates the percentage of the company's profits that Laboratorios Farmaceuticos ROVI distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2005
18.42 %
Jan 1, 2006
18.42 %
Jan 1, 2007
18.42 %
Jan 1, 2008
16.66 %
Jan 1, 2009
21.1 %
Jan 1, 2010
28.78 %
Jan 1, 2011
47.8 %
Jan 1, 2012
32.54 %
Jan 1, 2013
29.7 %
Jan 1, 2014
33.35 %
Jan 1, 2015
42.26 %
Jan 1, 2016
26.12 %
Jan 1, 2017
52.29 %
Jan 1, 2018
34.54 %
Jan 1, 2019
11.21 %
Price targets and forecasts for Laboratorios Farmaceuticos ROVI are not yet available.

Laboratorios Farmaceuticos ROVI Earnings Estimates

Laboratorios Farmaceuticos ROVI Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
11/5/20200.18EUR100.52 MEUR2020 Q3
7/27/20200.14EUR94.17 MEUR2020 Q2
5/13/20200.14EUR91.47 MEUR2020 Q1
2/26/20200.08EUR103.12 MEUR2019 Q4
11/7/20190.13EUR89 MEUR2019 Q3
7/30/20190.09EUR88.13 MEUR2019 Q2
5/8/20190.09EUR81.35 MEUR2019 Q1
2/26/20190.01EUR82.37 MEUR2018 Q4
11/6/20180.06EUR71.88 MEUR2018 Q3
7/26/20180.13EUR74.45 MEUR2018 Q2

EESG©

Eulerpool ESG Scorecard© for the Laboratorios Farmaceuticos ROVI stock

81/100
97
Environment
99
Social
47
Governance
E

Environment

20
Scope 1 - Direct Emissions9,565.8
Scope 2 - Indirect emissions from purchased energy9,243.18
Scope 3 - Indirect emissions within the value chain12,099.63
Total CO₂ emissions18,808.98
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees52.526
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Laboratorios Farmaceuticos ROVI shareholder structure

% Name
58.21927%
Norbel Invesrsiones, S.L.
Norbel Invesrsiones, S.L.
9.14544%
Indumenta Pueri, S.L.
Indumenta Pueri, S.L.
1.22583%
T. Rowe Price International Ltd
T. Rowe Price International Ltd
1.17273%
INVESCO Asset Management Limited
INVESCO Asset Management Limited
1.15898%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.04664%
ProfitlichSchmidlin AG
ProfitlichSchmidlin AG
0.92491%
Santander Private Banking Gestion, S.A., S.G.I.I.C.
Santander Private Banking Gestion, S.A., S.G.I.I.C.
0.9033%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.87228%
Pictet Asset Management Ltd.
Pictet Asset Management Ltd.
0.64233%
Invesco Advisers, Inc.
Invesco Advisers, Inc.
...

Laboratorios Farmaceuticos ROVI Executives and Management Board

JE

Mr. Juan Lopez-Belmonte Encina

Executive Chairman of the Board, Chief Executive Officer · since 2007

Compensation1.86 M EUR
JE

Mr. Javier Lopez-Belmonte Encina

First Executive Vice Chairman of the Board, Chief Financial Officer, General Manager of Industrial Operations · since 2001

Compensation729,000 EUR
IE

Mr. Ivan Jorge Lopez-Belmonte Encina

Second Executive Vice Chairman of the Board, Chief Commercial and Development Officer · since 2007

Compensation721,000 EUR
MP

Mr. Marcos Pena Pinto

Lead External Independent Director

Compensation80,000 EUR
MT

Ms. Marina Del Corral Tellez

Proprietary Director

Compensation80,000 EUR

Laboratorios Farmaceuticos ROVI Supply Chain

Frequently asked questions about Laboratorios Farmaceuticos ROVI

The business model of Laboratorios Farmaceuticos ROVI SA focuses on pharmaceutical research, development, manufacturing, and commercialization. The company operates in the specialty pharmaceuticals industry and specializes in the production of injectable pharmaceuticals and various other drugs. Laboratorios Farmaceuticos ROVI SA collaborates with international partners for the licensing and distribution of its products. With a strong emphasis on innovation and quality, the company aims to provide healthcare solutions through its unique product portfolio. Laboratorios Farmaceuticos ROVI SA actively pursues partnerships and collaborations to expand its market reach and continuously improve its product pipeline.

All fundamentals and in-depth analysis of Laboratorios Farmaceuticos ROVI

Our stock analysis for Laboratorios Farmaceuticos ROVI Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratorios Farmaceuticos ROVI Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Revenue→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Net Income→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI P/E→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI P/S→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI EBIT→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Dividend→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Directors Dealings→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Stocks→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Market capitalization→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Debt→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Liabilities→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Equity→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI AAQS→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Employees→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI ROE→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI ROA→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI ROCE→